Skip to main content
TipRanks
Go Ultimate75% OFF

Progyny (PGNY) AI Stock Analysis

712 Followers
PGNY

Progyny

(NASDAQ:PGNY)

Select Model
Rating:79Outperform
Price Target:$34.00â–¼(-7.38% Downside)
Action:reiterated
Date:11/05/26

The score is driven primarily by strong financial quality (low leverage and solid free cash flow) and a very positive earnings call with raised guidance, record client/lives additions, and ongoing buybacks. Technicals are supportive with price above major moving averages, though momentum is somewhat elevated. Valuation is the main limiter given the ~26 P/E and no dividend yield support.

Positive Factors
Client Growth and RetentionRecord client and covered-life additions expand the contracted base that drives recurring benefit administration revenue. Near-complete retention reinforces customer value, while the 2027 launches provide a visible foundation for continued scale over the next several quarters.
Negative Factors
Medical Cost InflationPersistently elevated medical cost inflation can pressure employer affordability, utilization economics, and Progyny’s margins. If costs remain high, clients may demand tighter benefit terms or greater efficiency, creating a durable constraint on profitable growth.

Progyny Key Performance Indicators (KPIs)

Fertility and Family Building ClientsCounts employer groups and other clients that buy Progyny’s fertility and family-building benefits, revealing sales momentum, market penetration, contract scale, and concentration risk from large customers.

100.00200.00300.00400.00500.00600.00Mar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Client counts have grown steadily and accelerated year-over-year, with clear inflection points tied to large renewals, enterprise wins and brownfield conversions; management says retention risk for 2027 is largely removed and early sales are pacing ahead, supporting the 1M+ lives target. Near-term summer seasonality and a comparability hit from a transition client temper sequential visibility, but strong cash conversion, margin expansion and active buybacks suggest these membership gains should convert into durable revenue and free cash flow tailwinds.

Data provided by:The Fly

Progyny (PGNY) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%60%PGNY+41.96%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.70B
Dividend Yield
―
Average Volume (3M)
1.09M
Price to Earnings (P/E)
31.8
Beta (1Y)
0.42
Revenue Growth
5.52%
EPS Growth
74.23%
Country
US
Employees
846
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Progyny Business Overview & Revenue Model

Company Description

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized b...

How the Company Makes Money

Progyny makes money primarily by selling fertility and family-building benefits solutions to employers (especially self-insured employers) on a contractual basis and administering those benefits for employer clients. Key revenue streams include: (1)...

Progyny Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:21.96%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call was strongly positive, with record new-client and covered-life additions, near 100% retention, healthy utilization, improved gross margins, strong cash generation, significant share repurchases and raised full-year guidance. The main challenges were a modest year-over-year decline in adjusted EBITDA margin, temporary third-quarter seasonality, elevated medical cost inflation and the currently immaterial contribution from Progyny Select.

Positive Updates

Record Third-Quarter Revenue and Profitability
Progyny reported record revenue and profitability for the third quarter. Revenue was above the midpoint of guidance and increased nearly 9% versus 2025.

Negative Updates

Adjusted EBITDA Margin Slightly Lower Year Over Year
Adjusted EBITDA margin was modestly lower than a year ago in the third quarter, although trailing twelve-month adjusted EBITDA margin remained at 17.1%.

Company Guidance

For full year 2026, Progyny is now projecting revenue of between $1.365 billion to $1.385 billion, reflecting growth of 5.9% to 7.5%; excluding the $48.5 million in revenue from the client who is under a transition of care agreement over the first half of 2025, full year revenue growth is projected to be 10.1% to 11.7%. Adjusted EBITDA is expected to be $235 million to $240 million, net income $107 million to $110.6 million, earnings per diluted share $1.30 and $1.35, and adjusted EPS $2.09 and $2.13 on the basis of approximately 82 million fully diluted shares. For the fourth quarter, revenue is expected to be $344.7 million to $364.7 million, for growth of 8.3% to 14.6%, adjusted EBITDA between $57.9 million to $62.9 million, net income between $28.5 million to $32.1 million, earnings per diluted share $0.36 and $0.41, and adjusted EPS $0.53 and $0.58 on the basis of 79 million fully diluted shares; at the midpoint of ranges for both the quarter and the year, the company expects to maintain a consistent adjusted EBITDA margin. The majority of the over 85 clients and 1.3 million lives added in the most recent selling season are expected to go live in the first quarter of 2027, with a meaningful number of lives, several hundred thousand, give or take, expected to launch midyear; once all the new clients are live in 2027, Progyny anticipates having more than 660 clients, representing 8.3 million covered lives.

Progyny Financial Statement Overview

Summary

Strong overall fundamentals driven by improving profitability and margins (TTM net margin ~6.8% and rising gross margin ~24.9%), very low leverage (debt-to-equity ~0.05), and solid free cash flow generation (TTM FCF ~$219M). Key offsets are historically volatile margins and inconsistent cash conversion (operating cash flow vs. net income fluctuating over time).

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.34B1.29B1.17B1.09B786.91M500.62M
Gross Profit332.99M304.48M253.36M238.80M167.32M112.14M
EBITDA140.40M100.38M86.38M72.97M26.04M33.74M
Net Income91.02M58.52M54.34M62.04M30.36M65.77M
Balance Sheet
Total Assets675.79M742.43M607.10M756.62M542.99M358.06M
Cash, Cash Equivalents and Short-Term Investments195.59M310.10M227.95M371.09M189.30M119.42M
Total Debt21.73M27.73M19.27M19.39M7.71M8.65M
Total Liabilities261.76M226.39M185.04M203.19M166.02M106.24M
Stockholders Equity414.03M516.04M422.06M553.43M376.97M251.82M
Cash Flow
Free Cash Flow219.24M191.78M173.70M185.17M77.15M23.91M
Operating Cash Flow253.13M210.19M179.10M188.81M80.39M26.04M
Investing Cash Flow199.98M-159.01M195.79M-200.53M-43.87M8.77M
Financing Cash Flow-454.78M-99.36M-309.88M-11.07M-7.86M-13.70M

Progyny Technical Analysis

Technical Analysis SentimentPositive
Last Price36.71

Price Trends

50DMA28.90Positive
100DMA28.90Positive
200DMA24.95Positive

Market Momentum

MACD2.52Negative
RSI77.81Negative
STOCH92.75Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PGNY, the sentiment is Positive. The current price of 36.71 is above the 20-day moving average (MA) of 32.06, above the 50-day MA of 28.90, and above the 200-day MA of 24.95, indicating a bullish trend. The MACD of 2.52 indicates Negative momentum. The RSI at 77.81 is Negative, neither overbought nor oversold. The STOCH value of 92.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PGNY.

Progyny Risk Analysis

Progyny disclosed 57 risk factors in its most recent earnings report. Progyny reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Progyny Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PGNY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PGNYPGNY79Outperform$2.70B31.8419.98%―5.52%74.23%
ELVELV76Outperform$93.75B18.4511.59%1.58%3.60%-4.06%
CICI75Outperform$77.49B12.9214.10%2.11%6.79%-0.38%
CVSCVS71Outperform$109.79B9.8814.13%3.10%6.77%2114.64%
UNHUNH62Neutral$349.16B22.1416.35%2.33%3.33%-8.75%
HUMHUM58Neutral$53.25B42.486.70%0.80%22.02%-3.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%PGNYCICVSHUMUNHELVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PGNY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PGNYProgyny, Inc.36.7111.8847.85%
CICigna294.0630.4411.54%
CVSCVS Health Corp85.8112.0416.31%
HUMHumana443.34222.93101.14%
UNHUnitedhealth Group Inc.389.6886.2228.41%
ELVElevance Health, Inc.433.93126.0640.95%

Progyny Corporate Events

Stock BuybackFinancial Disclosures

Progyny Reports Record Third-Quarter Financial Results and Growth

Positive
Nov 4, 2026

Progyny, Inc. is a global women’s health and family-building company offering fertility and pharmacy benefit services, along with pregnancy, parenting and menopause support for employer-sponsored covered lives. On November 4, 2026, the company report...

Business Operations and StrategyStock BuybackFinancial Disclosures

Progyny Posts Record Q2 Results, Expands Client Base

Positive
Aug 6, 2026

On August 6, 2026, Progyny reported record second‑quarter 2026 results, with revenue rising 5.3% year on year to $350.5 million and gross profit climbing 13% to $89.3 million, despite the loss of a large client that had contributed $17.2 million in t...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026